EA200000825A1 - Композиция, включающая ингибитор il-1 и полимер, контролирующий высвобождение - Google Patents

Композиция, включающая ингибитор il-1 и полимер, контролирующий высвобождение

Info

Publication number
EA200000825A1
EA200000825A1 EA200000825A EA200000825A EA200000825A1 EA 200000825 A1 EA200000825 A1 EA 200000825A1 EA 200000825 A EA200000825 A EA 200000825A EA 200000825 A EA200000825 A EA 200000825A EA 200000825 A1 EA200000825 A1 EA 200000825A1
Authority
EA
Eurasian Patent Office
Prior art keywords
liberation
inhibitor
composition including
effective amount
polymer monitoring
Prior art date
Application number
EA200000825A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид С. Коллинс
Майкл П. Бевилаква
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/798,414 external-priority patent/US6096728A/en
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA200000825A1 publication Critical patent/EA200000825A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
EA200000825A 1996-02-09 1997-02-10 Композиция, включающая ингибитор il-1 и полимер, контролирующий высвобождение EA200000825A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1141996P 1996-02-09 1996-02-09
US3278996P 1996-12-06 1996-12-06
US3624197P 1997-01-23 1997-01-23
US08/798,414 US6096728A (en) 1996-02-09 1997-02-07 Composition and method for treating inflammatory diseases
PCT/US1997/002131 WO1997028828A1 (en) 1996-02-09 1997-02-10 Composition comprising interleukin-1 inhibitor and controlled release polymer

Publications (1)

Publication Number Publication Date
EA200000825A1 true EA200000825A1 (ru) 2001-02-26

Family

ID=27486083

Family Applications (2)

Application Number Title Priority Date Filing Date
EA199800694A EA001792B1 (ru) 1996-02-09 1997-02-10 Композиция, включающая ингибитор il-1 и гидрогелевый эфир, и способы ее применения
EA200000825A EA200000825A1 (ru) 1996-02-09 1997-02-10 Композиция, включающая ингибитор il-1 и полимер, контролирующий высвобождение

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA199800694A EA001792B1 (ru) 1996-02-09 1997-02-10 Композиция, включающая ингибитор il-1 и гидрогелевый эфир, и способы ее применения

Country Status (19)

Country Link
EP (1) EP0904112B1 (enExample)
JP (2) JP4344404B2 (enExample)
KR (1) KR20040010739A (enExample)
CN (1) CN1215340A (enExample)
AT (1) ATE448797T1 (enExample)
AU (1) AU724960C (enExample)
BR (1) BR9707325A (enExample)
CA (2) CA2539273C (enExample)
CZ (1) CZ299025B6 (enExample)
DE (1) DE69739656D1 (enExample)
EA (2) EA001792B1 (enExample)
ES (1) ES2334726T3 (enExample)
HU (1) HU230160B1 (enExample)
IL (1) IL125552A0 (enExample)
MX (1) MX9806191A (enExample)
NO (1) NO983543L (enExample)
NZ (2) NZ331163A (enExample)
SK (1) SK288144B6 (enExample)
WO (1) WO1997028828A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0949931B1 (en) 1996-12-06 2008-08-27 Amgen Inc., Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000024770A2 (en) 1998-10-23 2000-05-04 Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
AT406054B (de) * 1998-11-04 2000-02-25 Andreas Bernkop-Schnuerch Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
US6576668B1 (en) * 1999-06-21 2003-06-10 Santen Pharmaceutical Co., Ltd. Remedies for arthrosis deformans
EP2322226A3 (en) * 1999-07-21 2011-08-17 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU5943201A (en) * 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
US7324635B2 (en) 2000-05-04 2008-01-29 Telemaze Llc Branch calling and caller ID based call routing telephone features
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
MXPA04006875A (es) * 2002-01-18 2004-12-06 Control Delivery Sys Inc Sistema de gel polimerico para suministro controlado de cofarmacos.
CA2485166A1 (en) 2002-05-21 2003-12-04 Amgen Inc. Substituted pyrimidinone and pyridinone compounds
NZ566539A (en) 2002-09-06 2010-01-29 Medarex Inc Therapeutic human anti-IL-1R1 monoclonal antibody
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
JP2007531738A (ja) 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド ＩＬ−１ｒａの凝集を低下させる方法
AU2005289685B2 (en) 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
CA2744999A1 (en) * 2004-12-30 2006-07-13 Genzyme Corporation Regimens for intra-articular viscosupplementation
CN101500606B (zh) * 2005-06-24 2013-12-04 杜克大学 基于热反应生物聚合物的直接药物送递系统
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
EP2217258B1 (en) 2007-11-14 2014-03-26 General Regeneratives Limited Use of interleukin-1 receptor antagonist as a myeloprotective agent
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
PL2259774T3 (pl) 2008-02-27 2013-04-30 Biomet Biologics Llc Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
KR200451958Y1 (ko) * 2008-10-09 2011-01-21 (주)에이치시티 모바일기기용 카드형 안테나장치
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
DE202009017772U1 (de) 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
PH12013501636A1 (en) * 2011-02-08 2013-10-14 Abbvie Inc Treatment of osteoarthritis and pain
PL2672985T3 (pl) 2011-02-11 2016-11-30 Bezcytrynianowe kompozycje farmaceutyczne zawierające anakinrę
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CA2847328A1 (en) 2011-09-02 2013-03-07 Novozymes Biopharma Dk A/S Oral formulations containing hyaluronic acid for sustained drug release
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
AU2014333953C1 (en) * 2013-10-08 2020-06-25 Ascendis Pharma A/S Hydrogel-linked IL-1ra prodrug
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
CZ309295B6 (cs) * 2015-03-09 2022-08-10 Contipro A.S. Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
EP3810098B1 (en) * 2018-06-22 2024-01-10 The Trustees Of Columbia University In The City Of New York Sustained release compositions and methods for treatment of temporomandibular joint degeneration
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP3886809A4 (en) 2018-11-28 2022-03-30 Genascence Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF OSTEOARTHRITIS
CA3147909A1 (en) 2019-08-08 2021-02-11 Avidence Therapeutics, Inc. Microsphere-based injectible celecoxib formulation
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
FI895955A7 (fi) 1988-04-15 1989-12-13 Protein Design Labs Inc Il-2-reseptorispesifisiä "kimeerisiä" vasta-aineita
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
WO1991003553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
AU7683391A (en) 1990-04-27 1991-11-27 Upjohn Company, The Modified interleukin-1 inhibitors
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
CA2119090A1 (en) * 1993-03-26 1994-09-27 Wayne R. Gombotz Compositions for controlled release of biologically active tgf-.beta.
JPH06321803A (ja) * 1993-05-17 1994-11-22 Kirin Brewery Co Ltd 水溶性ペプチドホルモンの徐放性製剤
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
WO1995010298A1 (en) * 1993-10-12 1995-04-20 Mary Lake Polan Method of contraception
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
WO1996000081A1 (en) * 1994-06-24 1996-01-04 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
IT1269989B (it) 1994-09-21 1997-04-16 Dompe Spa Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria

Also Published As

Publication number Publication date
NO983543D0 (no) 1998-07-31
JP2001500472A (ja) 2001-01-16
WO1997028828A1 (en) 1997-08-14
NZ503548A (en) 2001-09-28
AU724960B2 (en) 2000-10-05
JP4344404B2 (ja) 2009-10-14
EP0904112B1 (en) 2009-11-18
HU230160B1 (hu) 2015-09-28
HUP9902612A3 (en) 2001-11-28
IL125552A0 (en) 1999-03-12
CZ237398A3 (cs) 1999-09-15
EP0904112A1 (en) 1999-03-31
ATE448797T1 (de) 2009-12-15
CA2244664A1 (en) 1997-08-14
KR20040010739A (ko) 2004-01-31
AU724960C (en) 2002-08-15
JP2007211027A (ja) 2007-08-23
MX9806191A (es) 1998-10-31
CA2244664C (en) 2008-06-03
AU2121397A (en) 1997-08-28
CA2539273C (en) 2014-02-04
CN1215340A (zh) 1999-04-28
EA199800694A1 (ru) 1999-02-25
CA2539273A1 (en) 1997-08-14
CZ299025B6 (cs) 2008-04-02
SK103698A3 (en) 2001-01-18
SK288144B6 (sk) 2013-12-02
NZ331163A (en) 2000-07-28
EA001792B1 (ru) 2001-08-27
ES2334726T3 (es) 2010-03-15
DE69739656D1 (de) 2009-12-31
NO983543L (no) 1998-10-08
HUP9902612A2 (hu) 1999-11-29
BR9707325A (pt) 1999-04-13

Similar Documents

Publication Publication Date Title
EA200000825A1 (ru) Композиция, включающая ингибитор il-1 и полимер, контролирующий высвобождение
TR199902802T2 (xx) Kardiyovask�ler hastal�klar ve enflamatuar hastal�klar�n tedavisi i�in probukol monoesterleri.
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
ES2059965T3 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.
ATE88346T1 (de) Zusammensetzung mit gehalt an einem nichtsteroiden entzuendungshemmenden mittel und einem nichtbakterizidwirksamen tetracyclin.
FI971412A7 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasie n estäjinä
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
CL2010000383A1 (es) Esteres y amida de acidos carboxilicos que contienen un agente anti-inflamatorio no esteroidal; composicion farmaceutica: y su uso como inhibidores de 5-lipoxigenasa para prevenir o aliviar edema de tejidos, inflamacion y congestion de la conjuntiva, de la nubosidad de la cornea y daños a tejidos oftalmicos (divisional sol. 3109-99).
ES2171543T3 (es) Composiciones administrables topicamente que contienen derivados del acido 3-benzoilfenilacetico para el tratamiento de trastornos inflamatorios oftalmicos.
BR9710372A (pt) Composto composi-Æo farmac-utica e processos para o tratamento de uma doen-a inflamatÄria e de doen-as mediadas pela cliclooxigenase
DK0923378T3 (da) Fremme af sårheling ved kemisk modificerede tetracykliner
ATE371457T1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
BR9408478A (pt) Composto composição farmacéutica processos de tratmento de uma doença suscetível ao tratamento com agente anti-inflamatório não esteroidal e de tratamento de doenças medidas pela ciclo-oxigenase, sal farmaceuticamente eficaz e uso de um composto
ID27502A (id) Turunan-turunan 3-(amino-atau aminoalkil) piridinon dan penggunannya untuk pengobatan penyakit-penyakit yang berkaitan dengan hiv
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
FI973292A7 (fi) Substituoituja isoksatsoleja tulehduksen hoitamiseksi
ATE183393T1 (de) Kombinationspräparat, enthaltend 5-methylisoxazol-4-carbonsäure-(4-trifluormethy )-anilid und n-(4- trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
EA199700381A1 (ru) Диароматические соединения пропинила или диенила, промежуточные соединения, фармацевтические и косметические композиции на основе указанных соединений и применение косметических композиций
CO4940456A1 (es) Metodo antiinflamatorio
PT900563E (pt) Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas
ID21369A (id) Komposisi farmasi untuk penyembuhan penyakit yang disebabkan oleh virus
DE69635806D1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen
EA200001140A1 (ru) СОЕДИНЕНИЯ-ИНГИБИТОРЫ sPLA2 ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ